Melasma: The Pigment Problem Where Laser Treatment Often Makes It Worse

There is a pattern that repeats in aesthetic practices every summer. A patient arrives with symmetric brown patches across the cheeks and upper lip, having already spent a year and several thousand dollars on treatments that worked for six weeks and then came back darker. She has been sold a package. She has usually been sold laser.

Melasma treatment is the clearest example in aesthetic medicine of a condition being mismatched to a tool because the tool is the one in the room. The brown patch looks like sun damage, sun damage responds to energy devices, and so energy gets pointed at it. Then the pigment returns, often worse, and the next package is sold to fix the flare the last one caused.

What follows is the part that rarely gets said in a consultation where a device is being financed: melasma is not a spot, it is a chronic condition, and the treatments with the best published evidence are a prescription cream, a tinted sunscreen, and in selected patients an inexpensive oral drug borrowed from surgery.

Melasma is not a sun spot, and that distinction decides everything

The short answer: melasma is a chronic, relapsing pigmentary disorder with hormonal, genetic, vascular, and light-driven components, while a solar lentigo is a discrete patch of accumulated sun damage that can be removed.

The clinical picture is distinctive once you know it. Melasma presents as symmetric, ill-defined brown to gray-brown patches, most often in a centrofacial pattern across the forehead, upper lip, nose, and chin, or in a malar pattern over the cheekbones. It appears overwhelmingly in women, with published series commonly putting the female share around ninety percent, and it concentrates in Fitzpatrick skin types III through V. Latin American, South and East Asian, Middle Eastern, and Mediterranean populations carry a disproportionate share of it.

The triggers stack rather than compete. Ultraviolet radiation is the obvious one. Hormones are the underrated one, which is why melasma is often called the mask of pregnancy and why it flares on combined oral contraceptives. Genetics load the gun: a large majority of patients report a first-degree relative with the same thing. Heat matters independently of light, which is why hot yoga, cooking over a stove, and long drives aggravate it.

Then there is the finding that reframes the entire treatment plan. Histology in melasma skin does not show only excess melanin. It shows increased vascularity and elevated VEGF expression, increased mast cells, solar elastosis, and a disrupted basement membrane that allows pigment to drop into the dermis. That last detail is why melasma recurs when it is treated as a surface problem. You can clear the epidermal layer and leave the machinery that produced it fully intact, along with a reservoir of dermal pigment that no topical reaches.

"

A sun spot is a stain you can lift. Melasma is a faucet that stays on. Every treatment plan that ignores the difference produces the same result: clearance, then relapse, then a patient who believes her skin is the problem.

"

Why the obvious tool is the most common way this gets worse

The short answer: aggressive lasers and intense pulsed light frequently flare melasma, and repeated low-energy laser toning carries a documented risk of permanent mottled hypopigmentation.

This is the part that should be disclosed before any device touches a melasma patient, and often is not. Ablative resurfacing and high-energy IPL deliver exactly the stimulus melasma responds badly to, which is heat and inflammation in skin that is primed to make pigment. The result is post-inflammatory hyperpigmentation layered on top of the original problem, and it can take many months to settle. In darker skin tones, the risk arithmetic is steeper still, for the reasons laid out in cosmetic procedures on deeper skin tones.

The subtler failure is laser toning. Low-fluence 1064 nm Q-switched Nd:YAG treatment, delivered in weekly or biweekly series, became popular because it produces visible early lightening. Two problems emerged in the literature. Relapse rates after stopping were high, frequently within months. And repeated sessions produced punctate leukoderma, small confetti-like white spots caused by melanocyte injury, which is a complication patients almost never hear named and which does not reliably reverse. Trading a brown patch for permanent white dots is not a trade most people would accept if it were described in those words.

Picosecond devices and non-ablative fractional lasers have better safety profiles and some supportive data, but the honest summary of the device literature on melasma is that results are inconsistent, relapse is the norm, and energy belongs late in a plan rather than at the front of it. Melasma is the one pigmentary condition where the standard laser approach to sun spots and pigmentation does not transfer, and where the general laser versus chemical peel comparison tilts away from the device.

Superficial chemical peels sit in a more defensible position. Glycolic, salicylic, mandelic, and Jessner peels used as adjuncts to topical therapy can accelerate improvement modestly. Depth is the risk, not the concept, which is why the aggressive end of resurfacing described in the deep phenol peel is a poor fit for this diagnosis.

The treatments that actually hold up are the unglamorous ones

The short answer: rigorous photoprotection including visible light, and a prescription triple combination cream, remain the best-supported melasma treatment in the literature.

Start with light, because nothing else works without it. Standard broad spectrum sunscreen blocks ultraviolet radiation and does very little against visible light, and visible light in the blue-violet range independently induces pigmentation in skin types IV and above. The practical fix is specific: a tinted sunscreen containing iron oxides, which is what actually attenuates visible light, applied properly and reapplied. Add a wide-brimmed hat, and understand that car and office window glass transmits plenty of UVA. This is not a footnote to the plan. It is the plan's foundation, and patients who skip it relapse regardless of what else they are prescribed.

The topical anchor is the Kligman-style triple combination: hydroquinone, a retinoid, and a mid-potency corticosteroid, used in cycles rather than continuously. It has the deepest evidence base of any melasma topical. Two regulatory facts belong in the conversation. Hydroquinone is no longer available over the counter in the United States, following the 2020 CARES Act reform that removed it from the OTC monograph, so legitimate products are prescription items. And the FDA has repeatedly warned consumers about unapproved imported skin lightening creams, some of which have been found to contain mercury. Prolonged, uninterrupted use of high-strength hydroquinone also carries a rare risk of exogenous ochronosis, a paradoxical blue-black discoloration that is far harder to treat than what the patient started with. Cycling and supervision are not bureaucratic caution, they are the point.

Second-tier topicals with reasonable support include azelaic acid, cysteamine, tranexamic acid in topical form, niacinamide, and kojic acid. They are useful maintenance agents between hydroquinone cycles rather than replacements for it.

The oral drug that changed the conversation

The short answer: low-dose oral tranexamic acid has good trial and meta-analysis support in melasma, and it requires real screening because it is an antifibrinolytic.

Tranexamic acid entered aesthetics through the operating room, where it reduces bleeding and bruising, a story covered in tranexamic acid in cosmetic surgery. Dermatology adopted it after an incidental observation that patients taking it for other reasons lightened. The proposed mechanism fits melasma's biology better than a bleaching agent does: it interferes with the plasminogen pathway in keratinocytes, damping the UV-triggered signaling and the vascular component that topical lighteners never touch.

Typical dosing in the published protocols is 250 mg twice daily for roughly two to three months, and multiple meta-analyses report significant reductions in melasma severity scores compared with control. It is not for everyone. Personal or family history of clotting disorder, current estrogen-containing contraception, smoking, and cardiovascular risk factors all belong in the screening conversation, and the drug should not be prescribed casually or by anyone unwilling to take that history. Used properly, it is one of the more meaningful additions to melasma treatment in the last decade, and it costs a fraction of a laser package.

How to judge results and set a realistic timeline

The short answer: expect improvement measured over three to six months, expect maintenance indefinitely, and be skeptical of any photograph pair taken under different lighting.

Melasma is scored in the literature with MASI or modified MASI, a validated instrument that accounts for area, darkness, and homogeneity across facial zones. No clinic gallery uses it. What galleries do use is lighting, and melasma is unusually easy to flatter or exaggerate with a change in angle, flash, and white balance. The general discipline in how to read a before-and-after gallery matters here more than for almost any other condition, with one addition specific to pigment: ask for photographs taken at least six months after the end of treatment, not at the final session. Six-month images are where relapse shows up, which is precisely why they are rarely posted.

Set the timeline honestly at the start. This is a condition that is controlled rather than cured. Summer will be harder than winter. Pregnancy and hormonal changes will move the baseline. A good plan looks like a cycled topical regimen, daily tinted photoprotection, an oral agent where appropriate, adjunctive peels if they help, and devices considered only after the pigment has been quiet for a while and only with an informed patient.

The honest summary

Melasma is the most commonly mistreated pigment problem in aesthetics, and the reason is structural rather than clinical. The condition needs a diagnosis, a prescription, a sunscreen habit, and long-term follow-up. The economics of an aesthetic practice reward a device package. Those two facts pull in opposite directions, and patients pay for the gap in both money and skin.

The evidence is not ambiguous about the order of operations. Photoprotection that includes visible light comes first, and the tinted iron oxide detail is not optional. A properly cycled prescription topical regimen comes next. Oral tranexamic acid is a legitimate addition for screened patients. Superficial peels help at the margins. Lasers and intense pulsed light are the last consideration rather than the first, and in the wrong hands they are the leading cause of the flare that brought the patient in.

So the bottom line is a mindset rather than a product. If a provider frames melasma as something to remove in a series of six sessions, they have misunderstood the condition or are counting on you to. If they frame it as something to control for years, with a plan for the summer and a plan for relapse, you are in the right room. The patches will still be a nuisance. They will just stop getting worse every time you try to fix them.